AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Rho guanine nucleotide exchange factor 4

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9NR80

UPID:

ARHG4_HUMAN

Alternative names:

APC-stimulated guanine nucleotide exchange factor 1

Alternative UPACC:

Q9NR80; Q9HDC6; Q9UPP0

Background:

Rho guanine nucleotide exchange factor 4 (RhoGEF4), also known as APC-stimulated guanine nucleotide exchange factor 1, plays a pivotal role in cellular processes by acting as a guanine nucleotide exchange factor for RHOA, RAC1, and CDC42 GTPases. Its interaction with APC influences RAC1 GEF activity, contributing to cell migration and E-cadherin-mediated cell-cell adhesion. RhoGEF4 is essential for MMP9 up-regulation through the JNK signaling pathway in colorectal tumor cells and is implicated in tumor angiogenesis, intestinal adenoma formation, and tumor progression.

Therapeutic significance:

Understanding the role of Rho guanine nucleotide exchange factor 4 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.